{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:04:05Z","timestamp":1762506245735},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2369-14-281","type":"journal-article","created":{"date-parts":[[2013,12,28]],"date-time":"2013-12-28T00:01:34Z","timestamp":1388188894000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats"],"prefix":"10.1186","volume":"14","author":[{"given":"Eva","family":"Gravesen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Hofman-Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria L","family":"Mace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Olgaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,27]]},"reference":[{"key":"702_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/kisup.2012.37","volume":"2","author":"K Disease","year":"2012","unstructured":"Disease K, Improving Global Outcomes (KDIGO) Anemia Work Group: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012, 2: 279-335.","journal-title":"Kidney Int Suppl"},{"key":"702_CR2","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/ki.2008.489","volume":"74","author":"LT Pizzi","year":"2008","unstructured":"Pizzi LT, Bunz TJ, Coyne DW, Goldfarb DS, Singh AK: Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation. Kidney Int. 2008, 74: 1588-1595. 10.1038\/ki.2008.489.","journal-title":"Kidney Int"},{"key":"702_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1681\/ASN.2007050606","volume":"19","author":"T Kapoian","year":"2008","unstructured":"Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, et al: Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008, 19: 372-379. 10.1681\/ASN.2007050606.","journal-title":"J Am Soc Nephrol"},{"key":"702_CR4","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/sdi.12105","volume":"26","author":"S Shirazian","year":"2013","unstructured":"Shirazian S, Grant C, Miller I, Fishbane S: How can Erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The use of iron supplementation to reduce ESA dosing in hemodialysis. Semin Dial. 2013, 26: 534-536.","journal-title":"Semin Dial"},{"key":"702_CR5","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1111\/j.1523-1755.2004.00580.x","volume":"65","author":"CS Lim","year":"2004","unstructured":"Lim CS, Vaziri ND: The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int. 2004, 65: 1802-1809. 10.1111\/j.1523-1755.2004.00580.x.","journal-title":"Kidney Int"},{"key":"702_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1523-1755.2004.00716.x","volume":"66","author":"RA Zager","year":"2004","unstructured":"Zager RA, Johnson AC, Hanson SY: Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int. 2004, 66: 144-156. 10.1111\/j.1523-1755.2004.00716.x.","journal-title":"Kidney Int"},{"key":"702_CR7","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1097\/01.ASN.0000087087.61306.4A","volume":"14","author":"G Sengoelge","year":"2003","unstructured":"Sengoelge G, Kletzmayr J, Ferrara I, Perschl A, Horl WH, Sunder-Plassmann G: Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol. 2003, 14: 2639-2644. 10.1097\/01.ASN.0000087087.61306.4A.","journal-title":"J Am Soc Nephrol"},{"key":"702_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/ajkd.2002.33917","volume":"40","author":"RA Zager","year":"2002","unstructured":"Zager RA, Johnson AC, Hanson SY, Wasse H: Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002, 40: 90-103. 10.1053\/ajkd.2002.33917.","journal-title":"Am J Kidney Dis"},{"key":"702_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/1471-2369-14-167","volume":"14","author":"M Prats","year":"2013","unstructured":"Prats M, Font R, Garcia C, Cabre C, Jariod M, Vea AM: Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post- hoc analysis of a prospective study. BMC Nephrol. 2013, 14: 167-10.1186\/1471-2369-14-167.","journal-title":"BMC Nephrol"},{"key":"702_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1744-9987.2011.01037.x","volume":"16","author":"T Hryszko","year":"2012","unstructured":"Hryszko T, Rydzewska-Rosolowska A, Brzosko S, Koc-Zorawska E, Mysliwiec M: Low molecular weight iron dextran increases fibroblast growth factor-23 concentration, together with parathyroid hormone decrease in hemodialyzed patients. Ther Apher Dial. 2012, 16: 146-151. 10.1111\/j.1744-9987.2011.01037.x.","journal-title":"Ther Apher Dial"},{"key":"702_CR11","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jbmr.1923","volume":"28","author":"M Wolf","year":"2013","unstructured":"Wolf M, Koch TA, Bregman DB: Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013, 28: 1793-1803. 10.1002\/jbmr.1923.","journal-title":"J Bone Miner Res"},{"key":"702_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000327019","volume":"33","author":"Y Takeda","year":"2011","unstructured":"Takeda Y, Komaba H, Goto S, Fujii H, Umezu M, Hasegawa H, et al: Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol. 2011, 33: 421-426. 10.1159\/000327019.","journal-title":"Am J Nephrol"},{"key":"702_CR13","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1210\/jc.2008-2396","volume":"94","author":"BJ Schouten","year":"2009","unstructured":"Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG: FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009, 94: 2332-2337. 10.1210\/jc.2008-2396.","journal-title":"J Clin Endocrinol Metab"},{"key":"702_CR14","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","volume":"45","author":"Y Shimizu","year":"2009","unstructured":"Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, et al: Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009, 45: 814-816. 10.1016\/j.bone.2009.06.017.","journal-title":"Bone"},{"key":"702_CR15","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1161\/01.CIR.0000035250.66458.67","volume":"106","author":"T Drueke","year":"2002","unstructured":"Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, et al: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002, 106: 2212-2217. 10.1161\/01.CIR.0000035250.66458.67.","journal-title":"Circulation"},{"key":"702_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1152\/physrev.00002.2011","volume":"92","author":"A Martin","year":"2012","unstructured":"Martin A, David V, Quarles LD: Regulation and function of the FGF23\/klotho endocrine pathways. Physiol Rev. 2012, 92: 131-155. 10.1152\/physrev.00002.2011.","journal-title":"Physiol Rev"},{"key":"702_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00467-012-2347-x","volume":"28","author":"R Shroff","year":"2013","unstructured":"Shroff R: Phosphate is a vascular toxin. Pediatr Nephrol. 2013, 28: 583-593. 10.1007\/s00467-012-2347-x.","journal-title":"Pediatr Nephrol"},{"key":"702_CR18","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1681\/ASN.2012010048","volume":"23","author":"H Olauson","year":"2012","unstructured":"Olauson H, Lindberg K, Amin R, Jia T, Wernerson A, Andersson G, et al: Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism. J Am Soc Nephrol. 2012, 23: 1641-1651. 10.1681\/ASN.2012010048.","journal-title":"J Am Soc Nephrol"},{"key":"702_CR19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/ki.2012.176","volume":"82","author":"M Wolf","year":"2012","unstructured":"Wolf M: Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012, 82: 737-747. 10.1038\/ki.2012.176.","journal-title":"Kidney Int"},{"key":"702_CR20","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al: FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011, 121: 4393-4408. 10.1172\/JCI46122.","journal-title":"J Clin Invest"},{"key":"702_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/36285","volume":"390","author":"M Kuro-o","year":"1997","unstructured":"Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997, 390: 45-51. 10.1038\/36285.","journal-title":"Nature"},{"key":"702_CR22","doi-asserted-by":"publisher","first-page":"E1146","DOI":"10.1073\/pnas.1110905108","volume":"108","author":"EG Farrow","year":"2011","unstructured":"Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, et al: Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A. 2011, 108: E1146-E1155. 10.1073\/pnas.1110905108.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"702_CR23","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1210\/jc.2011-1239","volume":"96","author":"EA Imel","year":"2011","unstructured":"Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ: Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab. 2011, 96: 3541-3549. 10.1210\/jc.2011-1239.","journal-title":"J Clin Endocrinol Metab"},{"key":"702_CR24","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s13105-013-0266-3","volume":"69","author":"I Wright","year":"2013","unstructured":"Wright I, Blanco-Rojo R, Fernandez MC, Toxqui L, Moreno G, Perez-Granados AM, et al: Bone remodelling is reduced by recovery from iron-deficiency anaemia in premenopausal women. J Physiol Biochem. 2013, 69: 889-896. 10.1007\/s13105-013-0266-3.","journal-title":"J Physiol Biochem"},{"key":"702_CR25","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1136\/gut.2010.214312","volume":"61","author":"R Evstatiev","year":"2012","unstructured":"Evstatiev R, Gasche C: Iron sensing and signalling. Gut. 2012, 61: 933-952. 10.1136\/gut.2010.214312.","journal-title":"Gut"},{"key":"702_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1258\/acb.2008.008151","volume":"46","author":"BJ Schouten","year":"2009","unstructured":"Schouten BJ, Doogue MP, Soule SG, Hunt PJ: Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem. 2009, 46: 167-169. 10.1258\/acb.2008.008151.","journal-title":"Ann Clin Biochem"},{"key":"702_CR27","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1097\/01.ASN.0000024439.38838.03","volume":"13","author":"E Lewin","year":"2002","unstructured":"Lewin E, Garfia B, Recio FL, Rodriguez M, Olgaard K: Persistent downregulation of calcium- sensing receptor mRNA in rat parathyroids when severe secondary hyperparathyroidism is reversed by an isogenic kidney transplantation. J Am Soc Nephrol. 2002, 13: 2110-2116. 10.1097\/01.ASN.0000024439.38838.03.","journal-title":"J Am Soc Nephrol"},{"key":"702_CR28","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1681\/ASN.2005101136","volume":"17","author":"J Huan","year":"2006","unstructured":"Huan J, Olgaard K, Nielsen LB, Lewin E: Parathyroid hormone 7\u201384 induces hypocalcemia and inhibits the parathyroid hormone 1\u201384 secretory response to hypocalcemia in rats with intact parathyroid glands. J Am Soc Nephrol. 2006, 17: 1923-1930. 10.1681\/ASN.2005101136.","journal-title":"J Am Soc Nephrol"},{"key":"702_CR29","first-page":"4003","volume":"117","author":"IZ Ben Dov","year":"2007","unstructured":"Ben Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, et al: The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007, 117: 4003-4008.","journal-title":"J Clin Invest"},{"key":"702_CR30","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1681\/ASN.2009040427","volume":"21","author":"R Canalejo","year":"2010","unstructured":"Canalejo R, Canalejo A, Martinez-Moreno JM, Rodriguez-Ortiz ME, Estepa JC, Mendoza FJ, et al: FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol. 2010, 21: 1125-1135. 10.1681\/ASN.2009040427.","journal-title":"J Am Soc Nephrol"},{"key":"702_CR31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/81664","volume":"26","author":"KE White","year":"2000","unstructured":"White KE, Evans WE, O'Riordan JLH, Speer MC, Econs MS, Lorenz-Depiereux B, Grabowski M, Meitinger T, Strom TM: Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000, 26: 345-348. 10.1038\/81664.","journal-title":"Nat Genet"},{"key":"702_CR32","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1073\/pnas.101545198","volume":"98","author":"T Shimada","year":"2001","unstructured":"Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001, 98: 6500-6505. 10.1073\/pnas.101545198.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"702_CR33","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa020881","volume":"348","author":"KB Jonsson","year":"2003","unstructured":"Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al: Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003, 348: 1656-1663. 10.1056\/NEJMoa020881.","journal-title":"N Engl J Med"},{"key":"702_CR34","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1210\/jcem.82.2.3765","volume":"82","author":"MJ Econs","year":"1997","unstructured":"Econs MJ, McEnery PT: Autosomal dominant hypophosphatemic rickets\/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab. 1997, 82: 674-681. 10.1210\/jc.82.2.674.","journal-title":"J Clin Endocrinol Metab"},{"key":"702_CR35","first-page":"S93","volume":"15 Suppl 2","author":"BG Danielson","year":"2004","unstructured":"Danielson BG: Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol. 2004, 15 Suppl 2: S93-S98.","journal-title":"J Am Soc Nephrol"},{"key":"702_CR36","doi-asserted-by":"publisher","first-page":"820","DOI":"10.2215\/CJN.11721111","volume":"7","author":"T Isakova","year":"2012","unstructured":"Isakova T, Xie H, Barchi-Chung A, Smith K, Sowden N, Epstein M, et al: Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol. Clin J Am Soc Nephrol. 2012, 7: 820-828. 10.2215\/CJN.11721111.","journal-title":"Clin J Am Soc Nephrol"},{"key":"702_CR37","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2215\/CJN.04730510","volume":"6","author":"MG Vervloet","year":"2011","unstructured":"Vervloet MG, van Ittersum FJ, Buttler RM, Heijboer AC, Blankenstein MA, ter Wee PM: Effects of dietary phosphate and calcium intake on fibroblast growth factor-23. Clin J Am Soc Nephrol. 2011, 6: 383-389. 10.2215\/CJN.04730510.","journal-title":"Clin J Am Soc Nephrol"},{"key":"702_CR38","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1210\/jc.2012-1811","volume":"97","author":"ER Smith","year":"2012","unstructured":"Smith ER, Cai MM, McMahon LP, Holt SG: Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab. 2012, 97: 3357-3365. 10.1210\/jc.2012-1811.","journal-title":"J Clin Endocrinol Metab"},{"key":"702_CR39","doi-asserted-by":"publisher","first-page":"E352","DOI":"10.1210\/jc.2010-0589","volume":"95","author":"TO Carpenter","year":"2010","unstructured":"Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, et al: Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab. 2010, 95: E352-E357. 10.1210\/jc.2010-0589.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2369-14-281\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T02:32:20Z","timestamp":1630549940000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/1471-2369-14-281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["702"],"URL":"https:\/\/doi.org\/10.1186\/1471-2369-14-281","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"17 October 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"281"}}